Product Pipeline

Our business model allows us to pursue a broad range of cell and gene therapy product candidates in therapeutic areas of interest with high clinical and commercial potential.

STEM CELL THERAPEUTICS PORTFOLIO

We are an innovative cellular medicine company focussed on building a diverse stem cell therapy portfolio—from expanded stem cells for transplantation and hematological disorders, to stem-cell–derived immune cells for cancer, and iPSC-based regenerative medicine therapies.

We advance these programs internally and through strategic partnerships, including out-licensing from leading academic institutions and collaborations with pharma and biotech companies.

HOW WE DO IT

Our Capabilities

Integrated scientific and market analytics
Strategy and business development
Executing transactions from licensing to M&A
Research and manufacturing operations
Financing strategy and capital markets
Strategic commercial partnerships

TECHNOLOGY PARTNER

Icahn School of Medicine at Mount Sinai

Product Pipeline

To democratize cellular medicine, we leverage our significant platform technology expertise to expand our product portfolio spanning several large market therapeutic areas. Our diversified product pipeline includes both, pre-clinical and clinical-stage candidates.

Partnering Opportunities

For more information on our business development opportunities, please reach out to us using the link provided.

LEARN MORE ABOUT PARTNERING

OUR INVESTORS